Synapse - Genitourinary Oncology Service

Results (5696)

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2

Meeting Abstract

Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I. J.; Shapiro, J. D.; McDermott, R. S.; Hussain, A.; Patnaik, A.; Petrylak, D. P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG)

Meeting Abstract

Abu Zaid, M. I.; Milano, M. T.; Dinh, P. C.; Fossa, S.; Yang, H.; Feldman, D. R.; Travis, L. B.; Fung, C.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma

Meeting Abstract

Tannir, N. M.; Agarwal, N.; Dawson, N. A.; Motzer, R. J.; Jacobs, C. M.; Choueiri, T. K.; Hrom, J. S.; Geynisman, D. M.; Davis, N. B.; Figlin, R. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma

Meeting Abstract

Teo, M. Y.; Taplin, M. E.; Eastham, J. A.; Benoliel, H.; Kibel, A. S.; McBride, S. M.; Nguyen, P. L.; Gopalan, A.; Lis, R.; Scher, H. I.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED

Meeting Abstract

Vogelzang, N. J.; Kantoff, P. W.; Scholz, M. C.; Vacirca, J. L.; Dakhil, S. R.; Goel, S.; Harmon, M.; Tang, H.; Brown, B.; Armstrong, A. J.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT)

Meeting Abstract

Wong, N. C.; Dason, S.; Dean, L. W.; Isharwal, S.; Donoghue, M.; Jia, L.; Joseph, G.; Tap, W. D.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD

Meeting Abstract

Smith, M. R.; Sandhu, S. K.; Kelly, W. K.; Scher, H. I.; Efstathiou, E.; Lara, P.; Yu, E. Y.; George, D. J.; Chi, K. N.; Summa, J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors

Meeting Abstract

Sonpavde, G.; Hennessy, D.; Manitz, J.; Niegisch, G.; Powles, T.; Rosenberg, J. E.; Bajorin, D. F.; Apolo, A. B.; Pond, G. R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Tannir, N. M.; Frontera, O. A.; Hammers, H. J.; Carducci, M. A.; McDermott, D. F.; Salman, P.; Escudier, B.; Beuselinck, B.; Amin, A.; Porta, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N + I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214

Meeting Abstract

Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthelemy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Kollmannsberger, C. K.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save